Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
37.86
-0.01 (-0.03%)
Aug 13, 2025, 4:00 PM - Market closed
Collegium Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 707.01 | 631.45 | 566.77 | 463.93 | 276.87 | 310.02 | Upgrade
|
| Revenue Growth (YoY) | 22.61% | 11.41% | 22.17% | 67.56% | -10.69% | 4.49% | Upgrade
|
| Cost of Revenue | 88.3 | 83.53 | 79.72 | 118.19 | 59.07 | 69.5 | Upgrade
|
| Gross Profit | 618.71 | 547.92 | 487.05 | 345.74 | 217.8 | 240.52 | Upgrade
|
| Selling, General & Admin | 247.16 | 182.98 | 150.71 | 172.19 | 118.96 | 113.83 | Upgrade
|
| Research & Development | - | - | - | 3.98 | 9.45 | 9.77 | Upgrade
|
| Operating Expenses | 454.37 | 348.29 | 296.47 | 307.64 | 195.59 | 184.28 | Upgrade
|
| Operating Income | 164.33 | 199.63 | 190.58 | 38.11 | 22.21 | 56.23 | Upgrade
|
| Interest Expense | -82.3 | -73.97 | -83.34 | -63.21 | -21.01 | -28.88 | Upgrade
|
| Interest & Investment Income | 9.7 | 13.98 | 15.62 | 1.05 | 0.01 | 0.23 | Upgrade
|
| EBT Excluding Unusual Items | 91.73 | 139.63 | 122.85 | -24.06 | 1.2 | 27.58 | Upgrade
|
| Merger & Restructuring Charges | -37.25 | -29.6 | -15.12 | - | -4.58 | - | Upgrade
|
| Asset Writedown | - | - | - | -4.79 | - | - | Upgrade
|
| Legal Settlements | - | - | -8.5 | - | - | - | Upgrade
|
| Other Unusual Items | -1.48 | -11.47 | -23.5 | - | - | - | Upgrade
|
| Pretax Income | 53 | 98.57 | 75.73 | -28.85 | -3.37 | 27.58 | Upgrade
|
| Income Tax Expense | 16.73 | 29.38 | 27.58 | -3.85 | -74.89 | 0.83 | Upgrade
|
| Net Income | 36.27 | 69.19 | 48.16 | -25 | 71.52 | 26.75 | Upgrade
|
| Net Income to Common | 36.27 | 69.19 | 48.16 | -25 | 71.52 | 26.75 | Upgrade
|
| Net Income Growth | -63.69% | 43.68% | - | - | 167.33% | - | Upgrade
|
| Shares Outstanding (Basic) | 32 | 32 | 34 | 34 | 35 | 34 | Upgrade
|
| Shares Outstanding (Diluted) | 40 | 40 | 42 | 34 | 41 | 35 | Upgrade
|
| Shares Change (YoY) | -11.15% | -3.26% | 23.53% | -17.58% | 16.77% | 5.07% | Upgrade
|
| EPS (Basic) | 1.13 | 2.14 | 1.43 | -0.74 | 2.05 | 0.78 | Upgrade
|
| EPS (Diluted) | 1.06 | 1.86 | 1.29 | -0.74 | 1.86 | 0.76 | Upgrade
|
| EPS Growth | -56.39% | 43.56% | - | - | 144.25% | - | Upgrade
|
| Free Cash Flow | 201.81 | 203.33 | 274.29 | 122.61 | 101.61 | 88.4 | Upgrade
|
| Free Cash Flow Per Share | 5.07 | 5.03 | 6.56 | 3.62 | 2.48 | 2.52 | Upgrade
|
| Gross Margin | 87.51% | 86.77% | 85.93% | 74.52% | 78.66% | 77.58% | Upgrade
|
| Operating Margin | 23.24% | 31.61% | 33.63% | 8.21% | 8.02% | 18.14% | Upgrade
|
| Profit Margin | 5.13% | 10.96% | 8.50% | -5.39% | 25.83% | 8.63% | Upgrade
|
| Free Cash Flow Margin | 28.54% | 32.20% | 48.39% | 26.43% | 36.70% | 28.51% | Upgrade
|
| EBITDA | 375.77 | 368.79 | 339.83 | 172.26 | 91.12 | 117.78 | Upgrade
|
| EBITDA Margin | 53.15% | 58.40% | 59.96% | 37.13% | 32.91% | 37.99% | Upgrade
|
| D&A For EBITDA | 211.43 | 169.16 | 149.26 | 134.15 | 68.92 | 61.55 | Upgrade
|
| EBIT | 164.33 | 199.63 | 190.58 | 38.11 | 22.21 | 56.23 | Upgrade
|
| EBIT Margin | 23.24% | 31.61% | 33.63% | 8.21% | 8.02% | 18.14% | Upgrade
|
| Effective Tax Rate | 31.56% | 29.80% | 36.41% | - | - | 3.01% | Upgrade
|
| Advertising Expenses | - | 10.66 | 7.41 | 11.74 | 4.19 | 5.37 | Upgrade
|
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.